Clear All
754 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 1.25 mg Hormonal Therapy Estrogen Yes 1977 In Use
NA Estrogens, Conjugated Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) multiple Hormonal Therapy Estrogen Yes 1998 In Use
NA Chlorotrianisene Anisene 12 mg Hormonal Therapy Estrogen Yes 1992 1997 In Use
NA Estradiol Estrace 1 mg Hormonal Therapy Estrogen Yes 1998 In Use
NA Estrogens, Esterified Covaryx, Covaryx H.S., Menest, Ogen, Ortho-Est 2.5 mg Hormonal Therapy Estrogen Yes 1977 In Use
J9394 Fulvestrant (Fresnius) Fulvestrant (Fresnius) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
J9393 Fulvestrant (Teva) Fulvestrant (Teva) 25mg Hormonal Therapy Estrogen Receptor Antagonist No 2019 Dec 21, 2022 In Use
NA Elacestrant Orserdu Multiple Hormonal Therapy Estrogen Receptor Antagonist ERɑ Yes 2023 In Use
J9395 Fulvestrant Faslodex 25 mg Hormonal Therapy Estrogen Receptor Antagonist No 2002 Jan 1, 2004 In Use
NA Polyestradiol Phosphate Estradurin, Estradurine 40 mg Hormonal Therapy Estrogen Derivative No 1957 Aug 8, 2003 No Longer Used
J0896 Luspatercept Reblozyl 0.25mg Ancillary Therapy Erythropoiesis-Stimulating Agent No 2019 Jul 1, 2020 In Use
J0881 Darbepoetin alfa Aranesp 1 mcg Ancillary Therapy Erythropoiesis-Stimulating Agent No 2001 Jan 1, 2006 In Use
J0885 Epoetin Alfa Epogen, Procrit 1000 units Ancillary Therapy Erythropoiesis-Stimulating Agent No 1989 Jan 1, 2006 In Use
J2425 Palifermin Kepivance 50 mcg Ancillary Therapy Epithelial Growth Factor Keratinocyte Growth Factor/rHuKGF No 2004 Jan 1, 2006 In Use
Olutasidenib Rezlidhia 150mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2022 In Use
C9239 Temsirolimus Torisel 1 mg Chemotherapy Enzyme Inhibitor mTOR No 2007 Jan 1, 2008 Dec 31, 2008 No Longer Used
J8561 Everolimus Afinitor, Afinitor Disperz 0.25 mg Chemotherapy Enzyme Inhibitor mTOR Yes 2009 Jan 1, 2012 Dec 31, 2012 No Longer Used
J7527 Everolimus Afinitor, Afinitor Disperz 0.25 mg Chemotherapy Enzyme Inhibitor mTOR Yes 2009 Jan 1, 2013 In Use
Revumenib Revuforj 25mg, 110mg, 160mg Chemotherapy Enzyme Inhibitor KMT2A Yes 2024 In Use
NA Ivosidenib Tibsovo 250mg Chemotherapy Enzyme Inhibitor IDH1 Yes 2018 In Use
Tovorafenib Ojemda 25mg, 100mg Chemotherapy Enzyme Inhibitor BRAF, CRAF Yes 2024 In Use
NA Enasidenib mesylate Idhifa 50 mg Chemotherapy Enzyme Inhibitor IDH2 Yes 2017 In Use
NA Ruxolitinib Jakafi 20 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Umbralisib Ukoniq 260.2mg Chemotherapy Enzyme Inhibitor PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 Yes 2021 In Use
NA Rucaparib Rubraca 250 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.